BIOLIGHT(SZ:300246) Xin Lang Cai Jing·2025-09-22 11:28Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. participated in the "2025 Guangdong Listed Companies Investor Online Reception Day" on September 19, 2025, to engage with investors and discuss company performance and future strategies [1]. Group 1: Financial Performance - In the first half of 2025, the subsidiary Suzhou Junkang reported a net profit of 6.70 million yuan, with an operating loss of 4.37 million yuan, and has been consolidated into the company's financial statements [1]. - For the first half of 2025, the net profit attributable to shareholders of the listed company was 1.31 million yuan, an increase of 152.22% year-on-year. The total assets at the end of the reporting period were 2.41 billion yuan, a decrease of 3.66% from the beginning of the year [1]. - The company's equity attributable to the parent company was 1.22 billion yuan, an increase of 0.25% from the beginning of the year. Cost reduction measures led to a decrease in expenses, but revenue and product profits declined due to price reductions in blood dialysis consumables and other factors [1]. Group 2: Business Strategy - The company focuses on two main business segments: "Life Information and Support" and "Renal Medical," aiming to become a leader in critical care and nephrology [1]. - In the Life Information and Support segment, the company emphasizes clinical needs, leveraging technological advancements to innovate and create differentiated solutions [1]. - In the Renal Medical segment, the company is developing differentiated consumables for hemodialysis and exploring technologies in peritoneal dialysis and CRRT, with plans to launch a CRRT machine integrated with overall solutions [1]. Group 3: Future Plans - The company is actively seeking related targets in the industry chain and will communicate investor suggestions to the board [1]. - The dialysis device production line project at Suzhou Junkang is expected to be operational by June 30, 2026, with an annual production capacity of 12 million dialysis devices [1]. - Due to strategic adjustments, the German subsidiary is currently undergoing asset disposal [1].